Drugs / RSVt Vaccine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05687279 | Feb 2023 → Dec 2024 | respiratory syncytial virus infectious disease | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06705140 | Nov 2024 → Jun 2025 | respiratory syncytial virus bronchiolitis | Sanofi Pasteur, a Sanofi Company | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT06397768 | May 2024 → Sep 2025 | respiratory syncytial virus infectious disease | Sanofi Pasteur, a Sanofi Company | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT06252285 | Feb 2024 → Dec 2025 | respiratory syncytial virus bronchiolitis | Sanofi Pasteur, a Sanofi Company | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSVt Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05687279 ↗ |
| Modality | Vaccine | “live-attenuated Respiratory Syncytial Virus Vaccine” NCT05687279 ↗ |
| Route | Intranasal | “Route of Administration: Intranasal” NCT05687279 ↗ |